

Apex Labs launches advanced fungal infection capsules

30 June 2022 | News

The capsules have strengths of 65 and 130 mg



Chennai-based Apex Laboratories has launched an advanced form of Itraconazole Capsules Supra Bioavailable 65 and 130 mg, a potent therapeutic choice to effectively control fungal infections. Supra Bioavailable Itraconazole capsules deliver a higher percentage (90 per cent) of active medicine to the biological system, at a lesser dose. The advanced preparation also ensures lesser inter-individual variability which might translate into enhanced efficacy in the management of fungal infections.

Supra Bioavailable Itraconazole 65 mg & 130 mg capsules are prepared by Top spray granulation technology which is used to improve the dissolution rate of Itraconazole. It contains a solid dispersion of Itraconazole in a uniform non-pellet formulation. This novel technology enhances the bioavailability of poorly soluble drugs. The Technology utilises a solid dispersion of drug in a polymer to improve the absorption in the gastrointestinal tract to achieve "super bioavailability" compared to conventional preparations.